Endothelin-mediated increases in lung VEGF content promote vascular leak in young rats exposed to viral infection and hypoxia.
Viral respiratory infections increase the susceptibility of young animals to hypoxia-induced pulmonary edema formation. Previous work has shown that increased lung levels of endothelin (ET) contribute to this effect, though the mechanisms by which ET promotes vascular leak remain uncertain. Both in vitro and in vivo evidence suggests that ET can upregulate the production of VEGF, which is known to increase vascular permeability. We hypothesized that increases in lung ET promote increases in lung VEGF, which in turn increases vascular leak in the lung. Weanling rats were exposed to moderate hypoxia for 24 h while recovering from a mild viral respiratory infection, to hypoxia alone, or to viral infection alone. Lung VEGF mRNA and protein content were measured by RT-PCR and Western blotting, respectively. Animals exposed to hypoxia + virus demonstrated significant increases in lung VEGF mRNA and protein content. Immunohistochemical studies showed increased VEGF expression in alveolar septa and small pulmonary vessels in those animals. ET receptor blockade with bosentan prevented this increase in lung VEGF content, suggesting that ET promotes VEGF accumulation in the lung in this setting. Animals exposed to hypoxia + virus also demonstrated substantial increases in lung albumin extravasation, and those increases were blocked by both ET receptor blockade and VEGF antagonism. These findings suggest that ET-driven increases in lung VEGF content can contribute to the formation of pulmonary edema.
Carpenter
Todd C
TC
Developmental Lung Biology Laboratory, Box B-131, University of Colorado School of Medicine, 4200 E. 9th Avenue, Denver, CO 80262, USA. todd.carpenter@uchsc.edu
Schomberg
Stacey
S
Stenmark
Kurt R
KR
D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage; D000077300:Bosentan; D002199:Capillary Permeability / Q000187:drug effects; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000378:metabolism; D000860:Hypoxia / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D008297:Male; D011650:Pulmonary Alveoli / Q000378:metabolism* / Q000473:pathology / Q000821:virology; D011654:Pulmonary Edema / Q000378:metabolism / Q000473:pathology / Q000821:virology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D017466:Receptors, Endothelin / Q000378:metabolism*; D010253:Respirovirus Infections / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D029082:Sendai virus; D012709:Serum Albumin / Q000378:metabolism; D013449:Sulfonamides / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis*
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D012333:RNA, Messenger; D017466:Receptors, Endothelin; D012709:Serum Albumin; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D000077300:Bosentan